SPONSOR
Qilu Pharmaceutical Co., Ltd.
Total Trials
3
Recruiting
3
Phases
Phase 3, Phase 2, Phase 3
Conditions studied: NSCLCRelapsed or Refractory Multiple MyelomaCancer Treatment-Induced Thrombocytopenia
Qilu Pharmaceutical Co., Ltd. is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including NSCLC, Relapsed or Refractory Multiple Myeloma, Cancer Treatment-Induced Thrombocytopenia.
The trial portfolio spans Phase 3, Phase 2, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Qilu Pharmaceutical Co., Ltd.
How many clinical trials has Qilu Pharmaceutical Co., Ltd. sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by Qilu Pharmaceutical Co., Ltd., of which 3 are actively recruiting participants. These trials cover conditions including NSCLC, Relapsed or Refractory Multiple Myeloma, Cancer Treatment-Induced Thrombocytopenia. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Qilu Pharmaceutical Co., Ltd. research focus on?
Qilu Pharmaceutical Co., Ltd. clinical trials span NSCLC, Relapsed or Refractory Multiple Myeloma, Cancer Treatment-Induced Thrombocytopenia. The research pipeline includes Phase 3, Phase 2, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Qilu Pharmaceutical Co., Ltd. clinical trial?
To participate in a Qilu Pharmaceutical Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Qilu Pharmaceutical Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Qilu Pharmaceutical Co., Ltd.
NCT06754644 Phase 3
Recruiting
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
NSCLC
NCT07138209 Phase 3
Recruiting
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma
NCT06456528 Phase 2, Phase 3
Recruiting
QL0911 for the Treatment of Cancer Treatment-Induced Thrombocytopenia
Cancer Treatment-Induced Thrombocytopenia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology